Featured
Series B funding will accelerate development of new AI disease models for lung and heart conditions, while expanding the company's imaging analytics platform.
A robotics business is set to accelerate the rollout of artificial intelligence-powered harvesting technology after securing more than £14 million support.
Dogtooth Technologies has raised funding through equity investment from 24 Haymarket, EMV Capital and ACF Investors, alongside grants from Innovate UK and a venture leasing facility from Kineo Finance.
Cambridgeshire technology innovator Paragraf has added to its world-leading credentials by adding three international heavyweights to a new Advisory Committee. Two of them will also reinforce the Board.
A groundbreaking AI-powered device developed by Heartfelt Technologies in Cambridge could be set to revolutionise how heart failure is managed in the home, after receiving Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
The funding will be used to expand go-to-market teams across the US and Europe
University of Cambridge researchers have discovered what appears to be a transformative method of identifying mutations linked to genetic disorders.
Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1.
Signaloid, a Cambridge computing platform company providing hardware and binary-translation-based acceleration of AI, robotics, aerospace, and quantitative finance workloads, has launched the tapeout and preliminary specifications documents for its C0-ASIC processor.
Renaissance has announced a strategic partnership with CyberSmart, a UK-based cybersecurity provider focused on delivering continuous protection, compliance, and cyber risk management for small and medium-sized enterprises (SMEs).
Signaloid previews a new ASIC purpose-built for physical AI and robotics workloads.
CPI Enterprises, part of the High Value Manufacturing Catapult, has invested £500,000 in Cambridge-based life sciences company Verinnogen to support the development of a novel technology designed to improve the accuracy and reliability of cancer drug development.